The role of genetic polymorphisms in molecular targeted anticancer therapy - Monoclonal antibodies [Rola polimorfizmów genowych w terapii przeciwnowotworowej ukierunkowanej na cele molekularne - Przeciwciała monoklonalne]
Huszno J.,Klinika Onkologii Klinicznej I Doswiadczalnej |
Nowara E.,Klinika Onkologii Klinicznej I Doswiadczalnej |
Suwinski R.,II Klinika Radioterapii Centrum
Onkologia Polska | Year: 2011
The molecular targeted therapy is a new direction in systemic treatment of cancer patients. This drug acts on specific cancer cell structures - "molecular targets" such as receptors and tyrosine kinase - leading to a blockage in signal transduction and inhibition of proliferation or tumor regression. In spite of great selectivity, the molecular targeted therapy also causes toxicity. The aim of the intensively developing branch of science - pharmacogenetics - is to select patients, on the basis of their genotype, who achieve the greatest benefit from the treatment with the lowest risk of complications. In this article authors present results of the studies on the interrelatedness between genetic polymorphisms and treatment complications, as well as on the response of the tumor to monoclonal antibodies used in molecular targeted therapy. Copyright © 2011 Cornetis.